nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—MERTK—multiple sclerosis	0.276	0.597	CbGaD
Sunitinib—TYK2—multiple sclerosis	0.187	0.403	CbGaD
Sunitinib—ABCG2—Cladribine—multiple sclerosis	0.0169	0.135	CbGbCtD
Sunitinib—ABCG2—Mitoxantrone—multiple sclerosis	0.0123	0.0983	CbGbCtD
Sunitinib—ABCC4—Methotrexate—multiple sclerosis	0.00955	0.0762	CbGbCtD
Sunitinib—ABCC2—Dexamethasone—multiple sclerosis	0.00707	0.0564	CbGbCtD
Sunitinib—ABCG2—Dexamethasone—multiple sclerosis	0.00639	0.051	CbGbCtD
Sunitinib—ABCB1—Methylprednisolone—multiple sclerosis	0.00609	0.0486	CbGbCtD
Sunitinib—ABCC2—Methotrexate—multiple sclerosis	0.00568	0.0453	CbGbCtD
Sunitinib—CYP3A4—Fingolimod—multiple sclerosis	0.00566	0.0452	CbGbCtD
Sunitinib—ABCG2—Methotrexate—multiple sclerosis	0.00513	0.041	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.00472	0.0377	CbGbCtD
Sunitinib—CYP3A7—Dexamethasone—multiple sclerosis	0.00472	0.0377	CbGbCtD
Sunitinib—ABCB1—Mitoxantrone—multiple sclerosis	0.00444	0.0355	CbGbCtD
Sunitinib—ABCB1—Betamethasone—multiple sclerosis	0.00396	0.0316	CbGbCtD
Sunitinib—ABCB1—Prednisolone—multiple sclerosis	0.00391	0.0312	CbGbCtD
Sunitinib—ABCB1—Prednisone—multiple sclerosis	0.00369	0.0294	CbGbCtD
Sunitinib—CYP3A4—Methylprednisolone—multiple sclerosis	0.00365	0.0291	CbGbCtD
Sunitinib—CYP3A5—Dexamethasone—multiple sclerosis	0.00354	0.0282	CbGbCtD
Sunitinib—CYP3A4—Triamcinolone—multiple sclerosis	0.00277	0.0221	CbGbCtD
Sunitinib—CYP3A4—Mitoxantrone—multiple sclerosis	0.00266	0.0212	CbGbCtD
Sunitinib—CYP3A4—Betamethasone—multiple sclerosis	0.00237	0.0189	CbGbCtD
Sunitinib—CYP3A4—Prednisolone—multiple sclerosis	0.00234	0.0187	CbGbCtD
Sunitinib—ABCB1—Dexamethasone—multiple sclerosis	0.0023	0.0184	CbGbCtD
Sunitinib—CYP3A4—Prednisone—multiple sclerosis	0.00221	0.0176	CbGbCtD
Sunitinib—ABCB1—Methotrexate—multiple sclerosis	0.00185	0.0148	CbGbCtD
Sunitinib—CYP3A4—Dexamethasone—multiple sclerosis	0.00138	0.011	CbGbCtD
Sunitinib—CAMK2G—Azacitidine—Cladribine—multiple sclerosis	0.000558	0.253	CbGdCrCtD
Sunitinib—TLK2—Progesterone—Prednisolone—multiple sclerosis	0.000376	0.17	CbGdCrCtD
Sunitinib—RPS6KA1—Azacitidine—Cladribine—multiple sclerosis	0.000286	0.13	CbGdCrCtD
Sunitinib—Procainamide—BCHE—multiple sclerosis	0.000187	1	CrCbGaD
Sunitinib—MERTK—cerebellum—multiple sclerosis	0.000138	0.00124	CbGeAlD
Sunitinib—MAP4K5—medulla oblongata—multiple sclerosis	0.000138	0.00124	CbGeAlD
Sunitinib—MAP3K3—medulla oblongata—multiple sclerosis	0.000138	0.00124	CbGeAlD
Sunitinib—AXL—midbrain—multiple sclerosis	0.000138	0.00124	CbGeAlD
Sunitinib—MYLK—brain—multiple sclerosis	0.000138	0.00124	CbGeAlD
Sunitinib—CSNK1A1—nervous system—multiple sclerosis	0.000137	0.00123	CbGeAlD
Sunitinib—MAP3K12—central nervous system—multiple sclerosis	0.000137	0.00123	CbGeAlD
Sunitinib—CLK1—nervous system—multiple sclerosis	0.000136	0.00123	CbGeAlD
Sunitinib—RPS6KB1—spinal cord—multiple sclerosis	0.000136	0.00122	CbGeAlD
Sunitinib—PLK4—brain—multiple sclerosis	0.000136	0.00122	CbGeAlD
Sunitinib—MAP4K4—cerebellum—multiple sclerosis	0.000136	0.00122	CbGeAlD
Sunitinib—RET—spinal cord—multiple sclerosis	0.000135	0.00121	CbGeAlD
Sunitinib—STK4—brain—multiple sclerosis	0.000135	0.00121	CbGeAlD
Sunitinib—RPS6KA3—central nervous system—multiple sclerosis	0.000135	0.00121	CbGeAlD
Sunitinib—AXL—spinal cord—multiple sclerosis	0.000135	0.00121	CbGeAlD
Sunitinib—NUAK2—cerebellum—multiple sclerosis	0.000135	0.00121	CbGeAlD
Sunitinib—MAP2K1—central nervous system—multiple sclerosis	0.000134	0.0012	CbGeAlD
Sunitinib—CAMK2G—nervous system—multiple sclerosis	0.000134	0.0012	CbGeAlD
Sunitinib—BMP2K—nervous system—multiple sclerosis	0.000134	0.0012	CbGeAlD
Sunitinib—MAP3K12—cerebellum—multiple sclerosis	0.000134	0.0012	CbGeAlD
Sunitinib—FLT3—cerebellum—multiple sclerosis	0.000134	0.0012	CbGeAlD
Sunitinib—FLT1—medulla oblongata—multiple sclerosis	0.000133	0.0012	CbGeAlD
Sunitinib—SLK—midbrain—multiple sclerosis	0.000133	0.00119	CbGeAlD
Sunitinib—LRRK2—nervous system—multiple sclerosis	0.000133	0.00119	CbGeAlD
Sunitinib—PHKG2—brain—multiple sclerosis	0.000133	0.00119	CbGeAlD
Sunitinib—CSNK1A1—central nervous system—multiple sclerosis	0.000132	0.00119	CbGeAlD
Sunitinib—EPHB6—medulla oblongata—multiple sclerosis	0.000132	0.00119	CbGeAlD
Sunitinib—STK24—brain—multiple sclerosis	0.000132	0.00119	CbGeAlD
Sunitinib—RPS6KA3—cerebellum—multiple sclerosis	0.000132	0.00118	CbGeAlD
Sunitinib—CLK1—central nervous system—multiple sclerosis	0.000131	0.00118	CbGeAlD
Sunitinib—MAP2K1—cerebellum—multiple sclerosis	0.000131	0.00118	CbGeAlD
Sunitinib—PRKAA1—nervous system—multiple sclerosis	0.000131	0.00118	CbGeAlD
Sunitinib—DAPK2—brain—multiple sclerosis	0.00013	0.00117	CbGeAlD
Sunitinib—SLK—spinal cord—multiple sclerosis	0.00013	0.00116	CbGeAlD
Sunitinib—PTK2B—nervous system—multiple sclerosis	0.000129	0.00116	CbGeAlD
Sunitinib—CSNK1A1—cerebellum—multiple sclerosis	0.000129	0.00116	CbGeAlD
Sunitinib—FYN—midbrain—multiple sclerosis	0.000129	0.00116	CbGeAlD
Sunitinib—BMP2K—central nervous system—multiple sclerosis	0.000129	0.00116	CbGeAlD
Sunitinib—CAMK2G—central nervous system—multiple sclerosis	0.000129	0.00116	CbGeAlD
Sunitinib—FGFR2—spinal cord—multiple sclerosis	0.000128	0.00115	CbGeAlD
Sunitinib—CLK1—cerebellum—multiple sclerosis	0.000128	0.00115	CbGeAlD
Sunitinib—STK16—brain—multiple sclerosis	0.000128	0.00115	CbGeAlD
Sunitinib—LRRK2—central nervous system—multiple sclerosis	0.000128	0.00115	CbGeAlD
Sunitinib—JAK2—spinal cord—multiple sclerosis	0.000128	0.00115	CbGeAlD
Sunitinib—HIPK3—brain—multiple sclerosis	0.000128	0.00115	CbGeAlD
Sunitinib—HIPK2—brain—multiple sclerosis	0.000128	0.00115	CbGeAlD
Sunitinib—ALK—brain—multiple sclerosis	0.000128	0.00115	CbGeAlD
Sunitinib—TYRO3—brain—multiple sclerosis	0.000128	0.00115	CbGeAlD
Sunitinib—YES1—medulla oblongata—multiple sclerosis	0.000128	0.00115	CbGeAlD
Sunitinib—CSNK1E—nervous system—multiple sclerosis	0.000127	0.00114	CbGeAlD
Sunitinib—TNK1—brain—multiple sclerosis	0.000126	0.00113	CbGeAlD
Sunitinib—RIOK2—brain—multiple sclerosis	0.000126	0.00113	CbGeAlD
Sunitinib—MAP3K3—midbrain—multiple sclerosis	0.000126	0.00113	CbGeAlD
Sunitinib—MAP4K5—midbrain—multiple sclerosis	0.000126	0.00113	CbGeAlD
Sunitinib—CAMK2G—cerebellum—multiple sclerosis	0.000126	0.00113	CbGeAlD
Sunitinib—BMP2K—cerebellum—multiple sclerosis	0.000126	0.00113	CbGeAlD
Sunitinib—FYN—spinal cord—multiple sclerosis	0.000126	0.00113	CbGeAlD
Sunitinib—PRKAA1—central nervous system—multiple sclerosis	0.000126	0.00113	CbGeAlD
Sunitinib—TAOK3—medulla oblongata—multiple sclerosis	0.000126	0.00113	CbGeAlD
Sunitinib—IRAK4—nervous system—multiple sclerosis	0.000125	0.00113	CbGeAlD
Sunitinib—MAP4K1—brain—multiple sclerosis	0.000125	0.00112	CbGeAlD
Sunitinib—MAP3K19—brain—multiple sclerosis	0.000125	0.00112	CbGeAlD
Sunitinib—LRRK2—cerebellum—multiple sclerosis	0.000125	0.00112	CbGeAlD
Sunitinib—PTK2B—central nervous system—multiple sclerosis	0.000125	0.00112	CbGeAlD
Sunitinib—MAP3K3—spinal cord—multiple sclerosis	0.000123	0.00111	CbGeAlD
Sunitinib—MAP4K5—spinal cord—multiple sclerosis	0.000123	0.00111	CbGeAlD
Sunitinib—PRKAA1—cerebellum—multiple sclerosis	0.000123	0.00111	CbGeAlD
Sunitinib—DAPK3—brain—multiple sclerosis	0.000123	0.0011	CbGeAlD
Sunitinib—CSNK1E—central nervous system—multiple sclerosis	0.000123	0.0011	CbGeAlD
Sunitinib—ULK3—nervous system—multiple sclerosis	0.000123	0.0011	CbGeAlD
Sunitinib—MAP2K2—nervous system—multiple sclerosis	0.000123	0.0011	CbGeAlD
Sunitinib—FLT1—midbrain—multiple sclerosis	0.000122	0.0011	CbGeAlD
Sunitinib—PTK2B—cerebellum—multiple sclerosis	0.000122	0.00109	CbGeAlD
Sunitinib—MAP3K2—nervous system—multiple sclerosis	0.000122	0.00109	CbGeAlD
Sunitinib—CLK2—brain—multiple sclerosis	0.000122	0.00109	CbGeAlD
Sunitinib—MAP4K2—brain—multiple sclerosis	0.000121	0.00109	CbGeAlD
Sunitinib—CSNK1E—Danazol—Prednisone—multiple sclerosis	0.000121	0.0548	CbGdCrCtD
Sunitinib—IRAK4—central nervous system—multiple sclerosis	0.000121	0.00108	CbGeAlD
Sunitinib—EPHB6—midbrain—multiple sclerosis	0.000121	0.00108	CbGeAlD
Sunitinib—CSNK1E—cerebellum—multiple sclerosis	0.00012	0.00108	CbGeAlD
Sunitinib—FGFR1—cerebellum—multiple sclerosis	0.00012	0.00108	CbGeAlD
Sunitinib—STK3—brain—multiple sclerosis	0.000119	0.00107	CbGeAlD
Sunitinib—TBK1—nervous system—multiple sclerosis	0.000119	0.00107	CbGeAlD
Sunitinib—FLT1—spinal cord—multiple sclerosis	0.000119	0.00107	CbGeAlD
Sunitinib—TYK2—nervous system—multiple sclerosis	0.000118	0.00106	CbGeAlD
Sunitinib—ULK3—central nervous system—multiple sclerosis	0.000118	0.00106	CbGeAlD
Sunitinib—MAP2K2—central nervous system—multiple sclerosis	0.000118	0.00106	CbGeAlD
Sunitinib—IRAK4—cerebellum—multiple sclerosis	0.000118	0.00106	CbGeAlD
Sunitinib—ROCK1—brain—multiple sclerosis	0.000118	0.00106	CbGeAlD
Sunitinib—EPHB6—spinal cord—multiple sclerosis	0.000118	0.00106	CbGeAlD
Sunitinib—MAP3K2—central nervous system—multiple sclerosis	0.000117	0.00105	CbGeAlD
Sunitinib—YES1—midbrain—multiple sclerosis	0.000117	0.00105	CbGeAlD
Sunitinib—ULK3—cerebellum—multiple sclerosis	0.000115	0.00104	CbGeAlD
Sunitinib—MAP2K2—cerebellum—multiple sclerosis	0.000115	0.00104	CbGeAlD
Sunitinib—TAOK3—midbrain—multiple sclerosis	0.000115	0.00103	CbGeAlD
Sunitinib—DYRK1A—brain—multiple sclerosis	0.000115	0.00103	CbGeAlD
Sunitinib—TBK1—central nervous system—multiple sclerosis	0.000115	0.00103	CbGeAlD
Sunitinib—RPS6KB1—nervous system—multiple sclerosis	0.000115	0.00103	CbGeAlD
Sunitinib—MAP3K2—cerebellum—multiple sclerosis	0.000114	0.00103	CbGeAlD
Sunitinib—TYK2—central nervous system—multiple sclerosis	0.000114	0.00102	CbGeAlD
Sunitinib—FGR—nervous system—multiple sclerosis	0.000114	0.00102	CbGeAlD
Sunitinib—RET—nervous system—multiple sclerosis	0.000114	0.00102	CbGeAlD
Sunitinib—YES1—spinal cord—multiple sclerosis	0.000114	0.00102	CbGeAlD
Sunitinib—AXL—nervous system—multiple sclerosis	0.000113	0.00102	CbGeAlD
Sunitinib—MAP3K7—cerebellum—multiple sclerosis	0.000113	0.00102	CbGeAlD
Sunitinib—KDR—medulla oblongata—multiple sclerosis	0.000113	0.00101	CbGeAlD
Sunitinib—MAP2K5—medulla oblongata—multiple sclerosis	0.000113	0.00101	CbGeAlD
Sunitinib—TAOK3—spinal cord—multiple sclerosis	0.000112	0.00101	CbGeAlD
Sunitinib—MERTK—brain—multiple sclerosis	0.000112	0.00101	CbGeAlD
Sunitinib—TBK1—cerebellum—multiple sclerosis	0.000112	0.00101	CbGeAlD
Sunitinib—PDGFRA—spinal cord—multiple sclerosis	0.000112	0.001	CbGeAlD
Sunitinib—TYK2—cerebellum—multiple sclerosis	0.000111	0.001	CbGeAlD
Sunitinib—RPS6KB1—central nervous system—multiple sclerosis	0.00011	0.000991	CbGeAlD
Sunitinib—CSF1R—medulla oblongata—multiple sclerosis	0.00011	0.000989	CbGeAlD
Sunitinib—MAP4K4—brain—multiple sclerosis	0.00011	0.000989	CbGeAlD
Sunitinib—IRAK1—cerebellum—multiple sclerosis	0.00011	0.000987	CbGeAlD
Sunitinib—FGR—central nervous system—multiple sclerosis	0.00011	0.000985	CbGeAlD
Sunitinib—RET—central nervous system—multiple sclerosis	0.00011	0.000985	CbGeAlD
Sunitinib—NUAK2—brain—multiple sclerosis	0.000109	0.000982	CbGeAlD
Sunitinib—AXL—central nervous system—multiple sclerosis	0.000109	0.000981	CbGeAlD
Sunitinib—MAP3K12—brain—multiple sclerosis	0.000109	0.000975	CbGeAlD
Sunitinib—FGFR2—nervous system—multiple sclerosis	0.000108	0.000972	CbGeAlD
Sunitinib—RPS6KB1—cerebellum—multiple sclerosis	0.000108	0.000969	CbGeAlD
Sunitinib—JAK2—nervous system—multiple sclerosis	0.000108	0.000967	CbGeAlD
Sunitinib—RET—cerebellum—multiple sclerosis	0.000107	0.000963	CbGeAlD
Sunitinib—RPS6KA3—brain—multiple sclerosis	0.000107	0.000962	CbGeAlD
Sunitinib—AXL—cerebellum—multiple sclerosis	0.000107	0.000959	CbGeAlD
Sunitinib—MAP2K1—brain—multiple sclerosis	0.000106	0.000955	CbGeAlD
Sunitinib—FYN—nervous system—multiple sclerosis	0.000106	0.000954	CbGeAlD
Sunitinib—CSNK1A1—brain—multiple sclerosis	0.000105	0.000943	CbGeAlD
Sunitinib—CLK1—brain—multiple sclerosis	0.000104	0.000937	CbGeAlD
Sunitinib—FGFR2—central nervous system—multiple sclerosis	0.000104	0.000936	CbGeAlD
Sunitinib—MAP4K5—nervous system—multiple sclerosis	0.000104	0.000932	CbGeAlD
Sunitinib—MAP3K3—nervous system—multiple sclerosis	0.000104	0.000932	CbGeAlD
Sunitinib—JAK2—central nervous system—multiple sclerosis	0.000104	0.000931	CbGeAlD
Sunitinib—KDR—midbrain—multiple sclerosis	0.000103	0.000926	CbGeAlD
Sunitinib—MAP2K5—midbrain—multiple sclerosis	0.000103	0.000926	CbGeAlD
Sunitinib—SLK—cerebellum—multiple sclerosis	0.000103	0.000923	CbGeAlD
Sunitinib—CAMK2G—brain—multiple sclerosis	0.000102	0.00092	CbGeAlD
Sunitinib—BMP2K—brain—multiple sclerosis	0.000102	0.00092	CbGeAlD
Sunitinib—FYN—central nervous system—multiple sclerosis	0.000102	0.000918	CbGeAlD
Sunitinib—FGFR2—cerebellum—multiple sclerosis	0.000102	0.000915	CbGeAlD
Sunitinib—LRRK2—brain—multiple sclerosis	0.000101	0.000911	CbGeAlD
Sunitinib—JAK2—cerebellum—multiple sclerosis	0.000101	0.00091	CbGeAlD
Sunitinib—CSF1R—midbrain—multiple sclerosis	0.000101	0.000904	CbGeAlD
Sunitinib—KDR—spinal cord—multiple sclerosis	0.000101	0.000904	CbGeAlD
Sunitinib—MAP2K5—spinal cord—multiple sclerosis	0.000101	0.000904	CbGeAlD
Sunitinib—FLT1—nervous system—multiple sclerosis	0.0001	0.000901	CbGeAlD
Sunitinib—KIT—medulla oblongata—multiple sclerosis	0.0001	0.000898	CbGeAlD
Sunitinib—PRKAA1—brain—multiple sclerosis	0.0001	0.000898	CbGeAlD
Sunitinib—FYN—cerebellum—multiple sclerosis	9.99e-05	0.000897	CbGeAlD
Sunitinib—MAP4K5—central nervous system—multiple sclerosis	9.99e-05	0.000897	CbGeAlD
Sunitinib—MAP3K3—central nervous system—multiple sclerosis	9.99e-05	0.000897	CbGeAlD
Sunitinib—EPHB6—nervous system—multiple sclerosis	9.92e-05	0.000891	CbGeAlD
Sunitinib—PTK2B—brain—multiple sclerosis	9.89e-05	0.000888	CbGeAlD
Sunitinib—FLT4—brain—multiple sclerosis	9.86e-05	0.000886	CbGeAlD
Sunitinib—CSF1R—spinal cord—multiple sclerosis	9.82e-05	0.000882	CbGeAlD
Sunitinib—PDGFRB—medulla oblongata—multiple sclerosis	9.77e-05	0.000877	CbGeAlD
Sunitinib—MAP3K3—cerebellum—multiple sclerosis	9.76e-05	0.000877	CbGeAlD
Sunitinib—MAP4K5—cerebellum—multiple sclerosis	9.76e-05	0.000877	CbGeAlD
Sunitinib—CSNK1E—brain—multiple sclerosis	9.73e-05	0.000874	CbGeAlD
Sunitinib—FGFR1—brain—multiple sclerosis	9.73e-05	0.000874	CbGeAlD
Sunitinib—FLT1—central nervous system—multiple sclerosis	9.66e-05	0.000867	CbGeAlD
Sunitinib—YES1—nervous system—multiple sclerosis	9.58e-05	0.000861	CbGeAlD
Sunitinib—IRAK4—brain—multiple sclerosis	9.58e-05	0.00086	CbGeAlD
Sunitinib—EPHB6—central nervous system—multiple sclerosis	9.55e-05	0.000857	CbGeAlD
Sunitinib—STK10—nervous system—multiple sclerosis	9.5e-05	0.000853	CbGeAlD
Sunitinib—TAOK3—nervous system—multiple sclerosis	9.46e-05	0.00085	CbGeAlD
Sunitinib—FLT1—cerebellum—multiple sclerosis	9.44e-05	0.000848	CbGeAlD
Sunitinib—PDGFRA—nervous system—multiple sclerosis	9.4e-05	0.000844	CbGeAlD
Sunitinib—ULK3—brain—multiple sclerosis	9.36e-05	0.000841	CbGeAlD
Sunitinib—MAP2K2—brain—multiple sclerosis	9.36e-05	0.000841	CbGeAlD
Sunitinib—EPHB6—cerebellum—multiple sclerosis	9.33e-05	0.000838	CbGeAlD
Sunitinib—MAP3K2—brain—multiple sclerosis	9.3e-05	0.000835	CbGeAlD
Sunitinib—YES1—central nervous system—multiple sclerosis	9.22e-05	0.000829	CbGeAlD
Sunitinib—MAP3K7—brain—multiple sclerosis	9.21e-05	0.000827	CbGeAlD
Sunitinib—STK10—central nervous system—multiple sclerosis	9.14e-05	0.000821	CbGeAlD
Sunitinib—KIT—midbrain—multiple sclerosis	9.14e-05	0.000821	CbGeAlD
Sunitinib—TAOK3—central nervous system—multiple sclerosis	9.11e-05	0.000818	CbGeAlD
Sunitinib—TBK1—brain—multiple sclerosis	9.1e-05	0.000818	CbGeAlD
Sunitinib—PDGFRA—central nervous system—multiple sclerosis	9.05e-05	0.000813	CbGeAlD
Sunitinib—TYK2—brain—multiple sclerosis	9.04e-05	0.000812	CbGeAlD
Sunitinib—YES1—cerebellum—multiple sclerosis	9.02e-05	0.00081	CbGeAlD
Sunitinib—STK10—cerebellum—multiple sclerosis	8.94e-05	0.000803	CbGeAlD
Sunitinib—PDGFRB—midbrain—multiple sclerosis	8.93e-05	0.000802	CbGeAlD
Sunitinib—IRAK1—brain—multiple sclerosis	8.93e-05	0.000802	CbGeAlD
Sunitinib—KIT—spinal cord—multiple sclerosis	8.92e-05	0.000801	CbGeAlD
Sunitinib—TAOK3—cerebellum—multiple sclerosis	8.9e-05	0.000799	CbGeAlD
Sunitinib—PDGFRA—cerebellum—multiple sclerosis	8.84e-05	0.000794	CbGeAlD
Sunitinib—RPS6KB1—brain—multiple sclerosis	8.76e-05	0.000787	CbGeAlD
Sunitinib—PDGFRB—spinal cord—multiple sclerosis	8.71e-05	0.000782	CbGeAlD
Sunitinib—RET—brain—multiple sclerosis	8.71e-05	0.000782	CbGeAlD
Sunitinib—FGR—brain—multiple sclerosis	8.71e-05	0.000782	CbGeAlD
Sunitinib—AXL—brain—multiple sclerosis	8.67e-05	0.000779	CbGeAlD
Sunitinib—MAP2K5—nervous system—multiple sclerosis	8.48e-05	0.000762	CbGeAlD
Sunitinib—KDR—nervous system—multiple sclerosis	8.48e-05	0.000762	CbGeAlD
Sunitinib—CSNK1E—Betamethasone—Methylprednisolone—multiple sclerosis	8.45e-05	0.0383	CbGdCrCtD
Sunitinib—CSNK1E—Dexamethasone—Methylprednisolone—multiple sclerosis	8.45e-05	0.0383	CbGdCrCtD
Sunitinib—SLK—brain—multiple sclerosis	8.35e-05	0.00075	CbGeAlD
Sunitinib—CSNK1E—Betamethasone—Dexamethasone—multiple sclerosis	8.32e-05	0.0377	CbGdCrCtD
Sunitinib—CSNK1E—Dexamethasone—Betamethasone—multiple sclerosis	8.32e-05	0.0377	CbGdCrCtD
Sunitinib—CSF1R—nervous system—multiple sclerosis	8.28e-05	0.000743	CbGeAlD
Sunitinib—FGFR2—brain—multiple sclerosis	8.27e-05	0.000743	CbGeAlD
Sunitinib—JAK2—brain—multiple sclerosis	8.23e-05	0.000739	CbGeAlD
Sunitinib—KDR—central nervous system—multiple sclerosis	8.16e-05	0.000733	CbGeAlD
Sunitinib—MAP2K5—central nervous system—multiple sclerosis	8.16e-05	0.000733	CbGeAlD
Sunitinib—CSNK1E—Dexamethasone—Triamcinolone—multiple sclerosis	8.13e-05	0.0369	CbGdCrCtD
Sunitinib—CSNK1E—Betamethasone—Triamcinolone—multiple sclerosis	8.13e-05	0.0369	CbGdCrCtD
Sunitinib—FYN—brain—multiple sclerosis	8.11e-05	0.000729	CbGeAlD
Sunitinib—MAP2K5—cerebellum—multiple sclerosis	7.98e-05	0.000717	CbGeAlD
Sunitinib—KDR—cerebellum—multiple sclerosis	7.98e-05	0.000717	CbGeAlD
Sunitinib—CSF1R—central nervous system—multiple sclerosis	7.97e-05	0.000716	CbGeAlD
Sunitinib—MAP4K5—brain—multiple sclerosis	7.93e-05	0.000712	CbGeAlD
Sunitinib—MAP3K3—brain—multiple sclerosis	7.93e-05	0.000712	CbGeAlD
Sunitinib—CSF1R—cerebellum—multiple sclerosis	7.79e-05	0.000699	CbGeAlD
Sunitinib—CSNK1E—Dexamethasone—Prednisone—multiple sclerosis	7.72e-05	0.035	CbGdCrCtD
Sunitinib—CSNK1E—Betamethasone—Prednisone—multiple sclerosis	7.72e-05	0.035	CbGdCrCtD
Sunitinib—FLT1—brain—multiple sclerosis	7.67e-05	0.000689	CbGeAlD
Sunitinib—EPHB6—brain—multiple sclerosis	7.58e-05	0.000681	CbGeAlD
Sunitinib—CSNK1E—Dexamethasone—Prednisolone—multiple sclerosis	7.53e-05	0.0342	CbGdCrCtD
Sunitinib—CSNK1E—Betamethasone—Prednisolone—multiple sclerosis	7.53e-05	0.0342	CbGdCrCtD
Sunitinib—KIT—nervous system—multiple sclerosis	7.51e-05	0.000675	CbGeAlD
Sunitinib—PDGFRB—nervous system—multiple sclerosis	7.34e-05	0.000659	CbGeAlD
Sunitinib—YES1—brain—multiple sclerosis	7.32e-05	0.000658	CbGeAlD
Sunitinib—STK10—brain—multiple sclerosis	7.26e-05	0.000652	CbGeAlD
Sunitinib—KIT—central nervous system—multiple sclerosis	7.23e-05	0.00065	CbGeAlD
Sunitinib—TAOK3—brain—multiple sclerosis	7.23e-05	0.000649	CbGeAlD
Sunitinib—PDGFRA—brain—multiple sclerosis	7.18e-05	0.000645	CbGeAlD
Sunitinib—KIT—cerebellum—multiple sclerosis	7.07e-05	0.000635	CbGeAlD
Sunitinib—PDGFRB—central nervous system—multiple sclerosis	7.07e-05	0.000635	CbGeAlD
Sunitinib—PDGFRB—cerebellum—multiple sclerosis	6.91e-05	0.00062	CbGeAlD
Sunitinib—KDR—brain—multiple sclerosis	6.48e-05	0.000582	CbGeAlD
Sunitinib—MAP2K5—brain—multiple sclerosis	6.48e-05	0.000582	CbGeAlD
Sunitinib—CSF1R—brain—multiple sclerosis	6.33e-05	0.000568	CbGeAlD
Sunitinib—CHEK2—Danazol—Prednisone—multiple sclerosis	6.19e-05	0.0281	CbGdCrCtD
Sunitinib—KCNH2—medulla oblongata—multiple sclerosis	6.17e-05	0.000554	CbGeAlD
Sunitinib—Haemorrhage—Prednisone—multiple sclerosis	6.14e-05	0.00048	CcSEcCtD
Sunitinib—Erythema—Betamethasone—multiple sclerosis	6.14e-05	0.000479	CcSEcCtD
Sunitinib—Erythema—Dexamethasone—multiple sclerosis	6.14e-05	0.000479	CcSEcCtD
Sunitinib—Pancytopenia—Methotrexate—multiple sclerosis	6.09e-05	0.000476	CcSEcCtD
Sunitinib—Connective tissue disorder—Prednisone—multiple sclerosis	6.03e-05	0.000471	CcSEcCtD
Sunitinib—Oedema—Prednisolone—multiple sclerosis	6e-05	0.000469	CcSEcCtD
Sunitinib—Neutropenia—Methotrexate—multiple sclerosis	5.99e-05	0.000468	CcSEcCtD
Sunitinib—Dizziness—Azathioprine—multiple sclerosis	5.99e-05	0.000468	CcSEcCtD
Sunitinib—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	5.98e-05	0.000467	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Methotrexate—multiple sclerosis	5.96e-05	0.000465	CcSEcCtD
Sunitinib—Shock—Prednisolone—multiple sclerosis	5.91e-05	0.000461	CcSEcCtD
Sunitinib—Cough—Triamcinolone—multiple sclerosis	5.9e-05	0.000461	CcSEcCtD
Sunitinib—Convulsion—Triamcinolone—multiple sclerosis	5.86e-05	0.000458	CcSEcCtD
Sunitinib—Convulsion—Methylprednisolone—multiple sclerosis	5.85e-05	0.000457	CcSEcCtD
Sunitinib—ABCC4—nervous system—multiple sclerosis	5.84e-05	0.000525	CbGeAlD
Sunitinib—Hypertension—Triamcinolone—multiple sclerosis	5.84e-05	0.000456	CcSEcCtD
Sunitinib—Hypertension—Methylprednisolone—multiple sclerosis	5.83e-05	0.000455	CcSEcCtD
Sunitinib—Abdominal pain—Mitoxantrone—multiple sclerosis	5.78e-05	0.000452	CcSEcCtD
Sunitinib—Body temperature increased—Mitoxantrone—multiple sclerosis	5.78e-05	0.000452	CcSEcCtD
Sunitinib—Myalgia—Triamcinolone—multiple sclerosis	5.76e-05	0.00045	CcSEcCtD
Sunitinib—Vomiting—Azathioprine—multiple sclerosis	5.75e-05	0.00045	CcSEcCtD
Sunitinib—Pneumonia—Methotrexate—multiple sclerosis	5.75e-05	0.000449	CcSEcCtD
Sunitinib—Arthralgia—Methylprednisolone—multiple sclerosis	5.75e-05	0.000449	CcSEcCtD
Sunitinib—Myalgia—Methylprednisolone—multiple sclerosis	5.75e-05	0.000449	CcSEcCtD
Sunitinib—KIT—brain—multiple sclerosis	5.74e-05	0.000516	CbGeAlD
Sunitinib—Eye disorder—Prednisone—multiple sclerosis	5.74e-05	0.000448	CcSEcCtD
Sunitinib—Infestation NOS—Methotrexate—multiple sclerosis	5.72e-05	0.000447	CcSEcCtD
Sunitinib—Infestation—Methotrexate—multiple sclerosis	5.72e-05	0.000447	CcSEcCtD
Sunitinib—Rash—Azathioprine—multiple sclerosis	5.71e-05	0.000446	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	5.71e-05	0.000446	CcSEcCtD
Sunitinib—Dermatitis—Azathioprine—multiple sclerosis	5.7e-05	0.000445	CcSEcCtD
Sunitinib—Depression—Methotrexate—multiple sclerosis	5.7e-05	0.000445	CcSEcCtD
Sunitinib—Flushing—Prednisone—multiple sclerosis	5.7e-05	0.000445	CcSEcCtD
Sunitinib—Headache—Azathioprine—multiple sclerosis	5.67e-05	0.000443	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	5.67e-05	0.000443	CcSEcCtD
Sunitinib—KCNH2—midbrain—multiple sclerosis	5.64e-05	0.000507	CbGeAlD
Sunitinib—Dry mouth—Triamcinolone—multiple sclerosis	5.63e-05	0.00044	CcSEcCtD
Sunitinib—ABCC4—central nervous system—multiple sclerosis	5.63e-05	0.000505	CbGeAlD
Sunitinib—Renal failure—Methotrexate—multiple sclerosis	5.62e-05	0.000439	CcSEcCtD
Sunitinib—PDGFRB—brain—multiple sclerosis	5.61e-05	0.000504	CbGeAlD
Sunitinib—Angioedema—Dexamethasone—multiple sclerosis	5.61e-05	0.000438	CcSEcCtD
Sunitinib—Angioedema—Betamethasone—multiple sclerosis	5.61e-05	0.000438	CcSEcCtD
Sunitinib—Stomatitis—Methotrexate—multiple sclerosis	5.57e-05	0.000435	CcSEcCtD
Sunitinib—Angiopathy—Prednisone—multiple sclerosis	5.57e-05	0.000435	CcSEcCtD
Sunitinib—Immune system disorder—Prednisone—multiple sclerosis	5.55e-05	0.000433	CcSEcCtD
Sunitinib—Oedema—Triamcinolone—multiple sclerosis	5.52e-05	0.000431	CcSEcCtD
Sunitinib—KCNH2—spinal cord—multiple sclerosis	5.5e-05	0.000494	CbGeAlD
Sunitinib—ABCG2—medulla oblongata—multiple sclerosis	5.49e-05	0.000493	CbGeAlD
Sunitinib—Arrhythmia—Prednisone—multiple sclerosis	5.48e-05	0.000429	CcSEcCtD
Sunitinib—Infection—Triamcinolone—multiple sclerosis	5.48e-05	0.000428	CcSEcCtD
Sunitinib—Infection—Methylprednisolone—multiple sclerosis	5.47e-05	0.000428	CcSEcCtD
Sunitinib—Shock—Triamcinolone—multiple sclerosis	5.43e-05	0.000424	CcSEcCtD
Sunitinib—Insomnia—Prednisolone—multiple sclerosis	5.43e-05	0.000424	CcSEcCtD
Sunitinib—Alopecia—Prednisone—multiple sclerosis	5.43e-05	0.000424	CcSEcCtD
Sunitinib—Shock—Methylprednisolone—multiple sclerosis	5.42e-05	0.000423	CcSEcCtD
Sunitinib—Hepatobiliary disease—Methotrexate—multiple sclerosis	5.41e-05	0.000422	CcSEcCtD
Sunitinib—Nervous system disorder—Methylprednisolone—multiple sclerosis	5.4e-05	0.000422	CcSEcCtD
Sunitinib—Epistaxis—Methotrexate—multiple sclerosis	5.39e-05	0.000421	CcSEcCtD
Sunitinib—Hypersensitivity—Mitoxantrone—multiple sclerosis	5.39e-05	0.000421	CcSEcCtD
Sunitinib—Paraesthesia—Prednisolone—multiple sclerosis	5.39e-05	0.000421	CcSEcCtD
Sunitinib—Mental disorder—Prednisone—multiple sclerosis	5.38e-05	0.00042	CcSEcCtD
Sunitinib—Nausea—Azathioprine—multiple sclerosis	5.38e-05	0.00042	CcSEcCtD
Sunitinib—Skin disorder—Methylprednisolone—multiple sclerosis	5.35e-05	0.000418	CcSEcCtD
Sunitinib—Erythema—Prednisone—multiple sclerosis	5.34e-05	0.000418	CcSEcCtD
Sunitinib—Malnutrition—Prednisone—multiple sclerosis	5.34e-05	0.000418	CcSEcCtD
Sunitinib—Convulsion—Dexamethasone—multiple sclerosis	5.32e-05	0.000415	CcSEcCtD
Sunitinib—Convulsion—Betamethasone—multiple sclerosis	5.32e-05	0.000415	CcSEcCtD
Sunitinib—Hypertension—Dexamethasone—multiple sclerosis	5.3e-05	0.000414	CcSEcCtD
Sunitinib—Hypertension—Betamethasone—multiple sclerosis	5.3e-05	0.000414	CcSEcCtD
Sunitinib—Asthenia—Mitoxantrone—multiple sclerosis	5.25e-05	0.00041	CcSEcCtD
Sunitinib—Myalgia—Dexamethasone—multiple sclerosis	5.22e-05	0.000408	CcSEcCtD
Sunitinib—Myalgia—Betamethasone—multiple sclerosis	5.22e-05	0.000408	CcSEcCtD
Sunitinib—Haemoglobin—Methotrexate—multiple sclerosis	5.16e-05	0.000403	CcSEcCtD
Sunitinib—Pain—Prednisolone—multiple sclerosis	5.13e-05	0.000401	CcSEcCtD
Sunitinib—Hepatitis—Methotrexate—multiple sclerosis	5.13e-05	0.000401	CcSEcCtD
Sunitinib—Haemorrhage—Methotrexate—multiple sclerosis	5.13e-05	0.000401	CcSEcCtD
Sunitinib—Urinary tract disorder—Methotrexate—multiple sclerosis	5.07e-05	0.000396	CcSEcCtD
Sunitinib—Urethral disorder—Methotrexate—multiple sclerosis	5.03e-05	0.000393	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	5.03e-05	0.000393	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	5.02e-05	0.000392	CcSEcCtD
Sunitinib—ABCG2—midbrain—multiple sclerosis	5.02e-05	0.000451	CbGeAlD
Sunitinib—Oedema—Dexamethasone—multiple sclerosis	5.01e-05	0.000391	CcSEcCtD
Sunitinib—Oedema—Betamethasone—multiple sclerosis	5.01e-05	0.000391	CcSEcCtD
Sunitinib—Diarrhoea—Mitoxantrone—multiple sclerosis	5.01e-05	0.000391	CcSEcCtD
Sunitinib—Insomnia—Triamcinolone—multiple sclerosis	4.99e-05	0.00039	CcSEcCtD
Sunitinib—Insomnia—Methylprednisolone—multiple sclerosis	4.98e-05	0.000389	CcSEcCtD
Sunitinib—Infection—Betamethasone—multiple sclerosis	4.98e-05	0.000389	CcSEcCtD
Sunitinib—Infection—Dexamethasone—multiple sclerosis	4.98e-05	0.000389	CcSEcCtD
Sunitinib—Paraesthesia—Triamcinolone—multiple sclerosis	4.96e-05	0.000387	CcSEcCtD
Sunitinib—Paraesthesia—Methylprednisolone—multiple sclerosis	4.95e-05	0.000386	CcSEcCtD
Sunitinib—Anaemia—Prednisone—multiple sclerosis	4.94e-05	0.000386	CcSEcCtD
Sunitinib—Shock—Betamethasone—multiple sclerosis	4.93e-05	0.000385	CcSEcCtD
Sunitinib—Shock—Dexamethasone—multiple sclerosis	4.93e-05	0.000385	CcSEcCtD
Sunitinib—Dyspnoea—Triamcinolone—multiple sclerosis	4.92e-05	0.000384	CcSEcCtD
Sunitinib—Nervous system disorder—Betamethasone—multiple sclerosis	4.91e-05	0.000384	CcSEcCtD
Sunitinib—Nervous system disorder—Dexamethasone—multiple sclerosis	4.91e-05	0.000384	CcSEcCtD
Sunitinib—Thrombocytopenia—Dexamethasone—multiple sclerosis	4.9e-05	0.000383	CcSEcCtD
Sunitinib—Thrombocytopenia—Betamethasone—multiple sclerosis	4.9e-05	0.000383	CcSEcCtD
Sunitinib—ABCG2—spinal cord—multiple sclerosis	4.9e-05	0.00044	CbGeAlD
Sunitinib—Angioedema—Prednisone—multiple sclerosis	4.88e-05	0.000382	CcSEcCtD
Sunitinib—Dyspepsia—Triamcinolone—multiple sclerosis	4.86e-05	0.00038	CcSEcCtD
Sunitinib—Erythema multiforme—Methotrexate—multiple sclerosis	4.85e-05	0.000379	CcSEcCtD
Sunitinib—Dyspepsia—Methylprednisolone—multiple sclerosis	4.85e-05	0.000379	CcSEcCtD
Sunitinib—Eye disorder—Methotrexate—multiple sclerosis	4.8e-05	0.000375	CcSEcCtD
Sunitinib—Anorexia—Betamethasone—multiple sclerosis	4.77e-05	0.000373	CcSEcCtD
Sunitinib—Anorexia—Dexamethasone—multiple sclerosis	4.77e-05	0.000373	CcSEcCtD
Sunitinib—Cardiac disorder—Methotrexate—multiple sclerosis	4.76e-05	0.000372	CcSEcCtD
Sunitinib—Fatigue—Triamcinolone—multiple sclerosis	4.76e-05	0.000372	CcSEcCtD
Sunitinib—Fatigue—Methylprednisolone—multiple sclerosis	4.75e-05	0.000371	CcSEcCtD
Sunitinib—Pain—Triamcinolone—multiple sclerosis	4.72e-05	0.000369	CcSEcCtD
Sunitinib—Angiopathy—Methotrexate—multiple sclerosis	4.66e-05	0.000364	CcSEcCtD
Sunitinib—Vomiting—Mitoxantrone—multiple sclerosis	4.65e-05	0.000363	CcSEcCtD
Sunitinib—KCNH2—nervous system—multiple sclerosis	4.64e-05	0.000416	CbGeAlD
Sunitinib—Immune system disorder—Methotrexate—multiple sclerosis	4.63e-05	0.000362	CcSEcCtD
Sunitinib—Convulsion—Prednisone—multiple sclerosis	4.63e-05	0.000362	CcSEcCtD
Sunitinib—Mediastinal disorder—Methotrexate—multiple sclerosis	4.62e-05	0.000361	CcSEcCtD
Sunitinib—Hypertension—Prednisone—multiple sclerosis	4.61e-05	0.000361	CcSEcCtD
Sunitinib—Rash—Mitoxantrone—multiple sclerosis	4.61e-05	0.00036	CcSEcCtD
Sunitinib—Dermatitis—Mitoxantrone—multiple sclerosis	4.61e-05	0.00036	CcSEcCtD
Sunitinib—Chills—Methotrexate—multiple sclerosis	4.6e-05	0.00036	CcSEcCtD
Sunitinib—Headache—Mitoxantrone—multiple sclerosis	4.58e-05	0.000358	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	4.56e-05	0.000357	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	4.56e-05	0.000357	CcSEcCtD
Sunitinib—Myalgia—Prednisone—multiple sclerosis	4.55e-05	0.000355	CcSEcCtD
Sunitinib—Arthralgia—Prednisone—multiple sclerosis	4.55e-05	0.000355	CcSEcCtD
Sunitinib—Alopecia—Methotrexate—multiple sclerosis	4.53e-05	0.000354	CcSEcCtD
Sunitinib—Insomnia—Dexamethasone—multiple sclerosis	4.53e-05	0.000354	CcSEcCtD
Sunitinib—Insomnia—Betamethasone—multiple sclerosis	4.53e-05	0.000354	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	4.52e-05	0.000353	CcSEcCtD
Sunitinib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	4.5e-05	0.000352	CcSEcCtD
Sunitinib—Paraesthesia—Dexamethasone—multiple sclerosis	4.5e-05	0.000351	CcSEcCtD
Sunitinib—Paraesthesia—Betamethasone—multiple sclerosis	4.5e-05	0.000351	CcSEcCtD
Sunitinib—Mental disorder—Methotrexate—multiple sclerosis	4.5e-05	0.000351	CcSEcCtD
Sunitinib—Erythema—Methotrexate—multiple sclerosis	4.47e-05	0.000349	CcSEcCtD
Sunitinib—Malnutrition—Methotrexate—multiple sclerosis	4.47e-05	0.000349	CcSEcCtD
Sunitinib—ABCC4—brain—multiple sclerosis	4.47e-05	0.000401	CbGeAlD
Sunitinib—KCNH2—central nervous system—multiple sclerosis	4.46e-05	0.000401	CbGeAlD
Sunitinib—Hypersensitivity—Prednisolone—multiple sclerosis	4.42e-05	0.000346	CcSEcCtD
Sunitinib—Dyspepsia—Dexamethasone—multiple sclerosis	4.41e-05	0.000344	CcSEcCtD
Sunitinib—Dyspepsia—Betamethasone—multiple sclerosis	4.41e-05	0.000344	CcSEcCtD
Sunitinib—Dysgeusia—Methotrexate—multiple sclerosis	4.37e-05	0.000342	CcSEcCtD
Sunitinib—Body temperature increased—Triamcinolone—multiple sclerosis	4.36e-05	0.000341	CcSEcCtD
Sunitinib—KCNH2—cerebellum—multiple sclerosis	4.36e-05	0.000392	CbGeAlD
Sunitinib—Oedema—Prednisone—multiple sclerosis	4.36e-05	0.000341	CcSEcCtD
Sunitinib—Abdominal pain—Methylprednisolone—multiple sclerosis	4.35e-05	0.00034	CcSEcCtD
Sunitinib—Decreased appetite—Dexamethasone—multiple sclerosis	4.35e-05	0.00034	CcSEcCtD
Sunitinib—Decreased appetite—Betamethasone—multiple sclerosis	4.35e-05	0.00034	CcSEcCtD
Sunitinib—Nausea—Mitoxantrone—multiple sclerosis	4.35e-05	0.00034	CcSEcCtD
Sunitinib—Infection—Prednisone—multiple sclerosis	4.33e-05	0.000339	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	4.32e-05	0.000338	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	4.32e-05	0.000338	CcSEcCtD
Sunitinib—Back pain—Methotrexate—multiple sclerosis	4.32e-05	0.000338	CcSEcCtD
Sunitinib—Fatigue—Betamethasone—multiple sclerosis	4.32e-05	0.000337	CcSEcCtD
Sunitinib—Fatigue—Dexamethasone—multiple sclerosis	4.32e-05	0.000337	CcSEcCtD
Sunitinib—Shock—Prednisone—multiple sclerosis	4.29e-05	0.000335	CcSEcCtD
Sunitinib—Pain—Betamethasone—multiple sclerosis	4.28e-05	0.000335	CcSEcCtD
Sunitinib—Pain—Dexamethasone—multiple sclerosis	4.28e-05	0.000335	CcSEcCtD
Sunitinib—Nervous system disorder—Prednisone—multiple sclerosis	4.28e-05	0.000334	CcSEcCtD
Sunitinib—Skin disorder—Prednisone—multiple sclerosis	4.24e-05	0.000331	CcSEcCtD
Sunitinib—Anorexia—Prednisone—multiple sclerosis	4.16e-05	0.000325	CcSEcCtD
Sunitinib—Anaemia—Methotrexate—multiple sclerosis	4.13e-05	0.000323	CcSEcCtD
Sunitinib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	4.1e-05	0.00032	CcSEcCtD
Sunitinib—Gastrointestinal pain—Betamethasone—multiple sclerosis	4.1e-05	0.00032	CcSEcCtD
Sunitinib—Hypersensitivity—Triamcinolone—multiple sclerosis	4.07e-05	0.000318	CcSEcCtD
Sunitinib—Hypersensitivity—Methylprednisolone—multiple sclerosis	4.06e-05	0.000317	CcSEcCtD
Sunitinib—Leukopenia—Methotrexate—multiple sclerosis	4e-05	0.000312	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	3.97e-05	0.00031	CcSEcCtD
Sunitinib—Dizziness—Prednisolone—multiple sclerosis	3.97e-05	0.00031	CcSEcCtD
Sunitinib—Asthenia—Triamcinolone—multiple sclerosis	3.96e-05	0.000309	CcSEcCtD
Sunitinib—Abdominal pain—Betamethasone—multiple sclerosis	3.96e-05	0.000309	CcSEcCtD
Sunitinib—Abdominal pain—Dexamethasone—multiple sclerosis	3.96e-05	0.000309	CcSEcCtD
Sunitinib—Body temperature increased—Dexamethasone—multiple sclerosis	3.96e-05	0.000309	CcSEcCtD
Sunitinib—Body temperature increased—Betamethasone—multiple sclerosis	3.96e-05	0.000309	CcSEcCtD
Sunitinib—Asthenia—Methylprednisolone—multiple sclerosis	3.95e-05	0.000309	CcSEcCtD
Sunitinib—Insomnia—Prednisone—multiple sclerosis	3.95e-05	0.000308	CcSEcCtD
Sunitinib—Paraesthesia—Prednisone—multiple sclerosis	3.92e-05	0.000306	CcSEcCtD
Sunitinib—Pruritus—Triamcinolone—multiple sclerosis	3.91e-05	0.000305	CcSEcCtD
Sunitinib—Cough—Methotrexate—multiple sclerosis	3.9e-05	0.000305	CcSEcCtD
Sunitinib—Pruritus—Methylprednisolone—multiple sclerosis	3.9e-05	0.000304	CcSEcCtD
Sunitinib—ABCG2—cerebellum—multiple sclerosis	3.88e-05	0.000349	CbGeAlD
Sunitinib—Convulsion—Methotrexate—multiple sclerosis	3.87e-05	0.000302	CcSEcCtD
Sunitinib—Dyspepsia—Prednisone—multiple sclerosis	3.84e-05	0.0003	CcSEcCtD
Sunitinib—Myalgia—Methotrexate—multiple sclerosis	3.8e-05	0.000297	CcSEcCtD
Sunitinib—Chest pain—Methotrexate—multiple sclerosis	3.8e-05	0.000297	CcSEcCtD
Sunitinib—Arthralgia—Methotrexate—multiple sclerosis	3.8e-05	0.000297	CcSEcCtD
Sunitinib—Decreased appetite—Prednisone—multiple sclerosis	3.79e-05	0.000296	CcSEcCtD
Sunitinib—Rash—Prednisolone—multiple sclerosis	3.78e-05	0.000296	CcSEcCtD
Sunitinib—Dermatitis—Prednisolone—multiple sclerosis	3.78e-05	0.000295	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	3.78e-05	0.000295	CcSEcCtD
Sunitinib—Diarrhoea—Methylprednisolone—multiple sclerosis	3.77e-05	0.000294	CcSEcCtD
Sunitinib—Fatigue—Prednisone—multiple sclerosis	3.76e-05	0.000294	CcSEcCtD
Sunitinib—Headache—Prednisolone—multiple sclerosis	3.76e-05	0.000294	CcSEcCtD
Sunitinib—ABCB1—retina—multiple sclerosis	3.75e-05	0.000336	CbGeAlD
Sunitinib—Constipation—Prednisone—multiple sclerosis	3.73e-05	0.000291	CcSEcCtD
Sunitinib—Dizziness—Triamcinolone—multiple sclerosis	3.65e-05	0.000285	CcSEcCtD
Sunitinib—Dizziness—Methylprednisolone—multiple sclerosis	3.64e-05	0.000285	CcSEcCtD
Sunitinib—Infection—Methotrexate—multiple sclerosis	3.62e-05	0.000283	CcSEcCtD
Sunitinib—Asthenia—Dexamethasone—multiple sclerosis	3.59e-05	0.000281	CcSEcCtD
Sunitinib—Asthenia—Betamethasone—multiple sclerosis	3.59e-05	0.000281	CcSEcCtD
Sunitinib—Nervous system disorder—Methotrexate—multiple sclerosis	3.58e-05	0.000279	CcSEcCtD
Sunitinib—Thrombocytopenia—Methotrexate—multiple sclerosis	3.57e-05	0.000279	CcSEcCtD
Sunitinib—Gastrointestinal pain—Prednisone—multiple sclerosis	3.57e-05	0.000279	CcSEcCtD
Sunitinib—Nausea—Prednisolone—multiple sclerosis	3.57e-05	0.000279	CcSEcCtD
Sunitinib—KCNH2—brain—multiple sclerosis	3.54e-05	0.000318	CbGeAlD
Sunitinib—Pruritus—Dexamethasone—multiple sclerosis	3.54e-05	0.000277	CcSEcCtD
Sunitinib—Pruritus—Betamethasone—multiple sclerosis	3.54e-05	0.000277	CcSEcCtD
Sunitinib—Skin disorder—Methotrexate—multiple sclerosis	3.54e-05	0.000277	CcSEcCtD
Sunitinib—Vomiting—Triamcinolone—multiple sclerosis	3.51e-05	0.000274	CcSEcCtD
Sunitinib—Vomiting—Methylprednisolone—multiple sclerosis	3.5e-05	0.000274	CcSEcCtD
Sunitinib—Rash—Triamcinolone—multiple sclerosis	3.48e-05	0.000272	CcSEcCtD
Sunitinib—Dermatitis—Triamcinolone—multiple sclerosis	3.48e-05	0.000272	CcSEcCtD
Sunitinib—Anorexia—Methotrexate—multiple sclerosis	3.47e-05	0.000271	CcSEcCtD
Sunitinib—Rash—Methylprednisolone—multiple sclerosis	3.47e-05	0.000271	CcSEcCtD
Sunitinib—Dermatitis—Methylprednisolone—multiple sclerosis	3.47e-05	0.000271	CcSEcCtD
Sunitinib—Headache—Triamcinolone—multiple sclerosis	3.46e-05	0.00027	CcSEcCtD
Sunitinib—Headache—Methylprednisolone—multiple sclerosis	3.45e-05	0.00027	CcSEcCtD
Sunitinib—Abdominal pain—Prednisone—multiple sclerosis	3.45e-05	0.000269	CcSEcCtD
Sunitinib—Body temperature increased—Prednisone—multiple sclerosis	3.45e-05	0.000269	CcSEcCtD
Sunitinib—Diarrhoea—Betamethasone—multiple sclerosis	3.43e-05	0.000268	CcSEcCtD
Sunitinib—Diarrhoea—Dexamethasone—multiple sclerosis	3.43e-05	0.000268	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	3.32e-05	0.000259	CcSEcCtD
Sunitinib—Dizziness—Betamethasone—multiple sclerosis	3.31e-05	0.000259	CcSEcCtD
Sunitinib—Dizziness—Dexamethasone—multiple sclerosis	3.31e-05	0.000259	CcSEcCtD
Sunitinib—Insomnia—Methotrexate—multiple sclerosis	3.3e-05	0.000258	CcSEcCtD
Sunitinib—Nausea—Triamcinolone—multiple sclerosis	3.28e-05	0.000256	CcSEcCtD
Sunitinib—Paraesthesia—Methotrexate—multiple sclerosis	3.27e-05	0.000256	CcSEcCtD
Sunitinib—Nausea—Methylprednisolone—multiple sclerosis	3.27e-05	0.000256	CcSEcCtD
Sunitinib—Dyspnoea—Methotrexate—multiple sclerosis	3.25e-05	0.000254	CcSEcCtD
Sunitinib—Hypersensitivity—Prednisone—multiple sclerosis	3.21e-05	0.000251	CcSEcCtD
Sunitinib—Dyspepsia—Methotrexate—multiple sclerosis	3.21e-05	0.000251	CcSEcCtD
Sunitinib—Vomiting—Betamethasone—multiple sclerosis	3.18e-05	0.000249	CcSEcCtD
Sunitinib—Vomiting—Dexamethasone—multiple sclerosis	3.18e-05	0.000249	CcSEcCtD
Sunitinib—Decreased appetite—Methotrexate—multiple sclerosis	3.17e-05	0.000248	CcSEcCtD
Sunitinib—Rash—Betamethasone—multiple sclerosis	3.16e-05	0.000247	CcSEcCtD
Sunitinib—Rash—Dexamethasone—multiple sclerosis	3.16e-05	0.000247	CcSEcCtD
Sunitinib—Dermatitis—Betamethasone—multiple sclerosis	3.16e-05	0.000247	CcSEcCtD
Sunitinib—Dermatitis—Dexamethasone—multiple sclerosis	3.16e-05	0.000247	CcSEcCtD
Sunitinib—ABCG2—brain—multiple sclerosis	3.15e-05	0.000283	CbGeAlD
Sunitinib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	3.15e-05	0.000246	CcSEcCtD
Sunitinib—Fatigue—Methotrexate—multiple sclerosis	3.14e-05	0.000246	CcSEcCtD
Sunitinib—Headache—Dexamethasone—multiple sclerosis	3.14e-05	0.000245	CcSEcCtD
Sunitinib—Headache—Betamethasone—multiple sclerosis	3.14e-05	0.000245	CcSEcCtD
Sunitinib—Asthenia—Prednisone—multiple sclerosis	3.13e-05	0.000245	CcSEcCtD
Sunitinib—Pain—Methotrexate—multiple sclerosis	3.12e-05	0.000244	CcSEcCtD
Sunitinib—Pruritus—Prednisone—multiple sclerosis	3.09e-05	0.000241	CcSEcCtD
Sunitinib—Diarrhoea—Prednisone—multiple sclerosis	2.98e-05	0.000233	CcSEcCtD
Sunitinib—Gastrointestinal pain—Methotrexate—multiple sclerosis	2.98e-05	0.000233	CcSEcCtD
Sunitinib—Nausea—Betamethasone—multiple sclerosis	2.98e-05	0.000232	CcSEcCtD
Sunitinib—Nausea—Dexamethasone—multiple sclerosis	2.98e-05	0.000232	CcSEcCtD
Sunitinib—Dizziness—Prednisone—multiple sclerosis	2.88e-05	0.000225	CcSEcCtD
Sunitinib—Body temperature increased—Methotrexate—multiple sclerosis	2.88e-05	0.000225	CcSEcCtD
Sunitinib—Abdominal pain—Methotrexate—multiple sclerosis	2.88e-05	0.000225	CcSEcCtD
Sunitinib—CYP3A4—nervous system—multiple sclerosis	2.87e-05	0.000258	CbGeAlD
Sunitinib—Vomiting—Prednisone—multiple sclerosis	2.77e-05	0.000217	CcSEcCtD
Sunitinib—CYP3A4—central nervous system—multiple sclerosis	2.77e-05	0.000248	CbGeAlD
Sunitinib—Rash—Prednisone—multiple sclerosis	2.75e-05	0.000215	CcSEcCtD
Sunitinib—Dermatitis—Prednisone—multiple sclerosis	2.75e-05	0.000215	CcSEcCtD
Sunitinib—Headache—Prednisone—multiple sclerosis	2.73e-05	0.000213	CcSEcCtD
Sunitinib—ABCB1—medulla oblongata—multiple sclerosis	2.71e-05	0.000243	CbGeAlD
Sunitinib—Hypersensitivity—Methotrexate—multiple sclerosis	2.69e-05	0.00021	CcSEcCtD
Sunitinib—Asthenia—Methotrexate—multiple sclerosis	2.62e-05	0.000204	CcSEcCtD
Sunitinib—Nausea—Prednisone—multiple sclerosis	2.59e-05	0.000202	CcSEcCtD
Sunitinib—Pruritus—Methotrexate—multiple sclerosis	2.58e-05	0.000201	CcSEcCtD
Sunitinib—Diarrhoea—Methotrexate—multiple sclerosis	2.49e-05	0.000195	CcSEcCtD
Sunitinib—ABCB1—midbrain—multiple sclerosis	2.47e-05	0.000222	CbGeAlD
Sunitinib—ABCB1—spinal cord—multiple sclerosis	2.41e-05	0.000217	CbGeAlD
Sunitinib—Dizziness—Methotrexate—multiple sclerosis	2.41e-05	0.000188	CcSEcCtD
Sunitinib—Vomiting—Methotrexate—multiple sclerosis	2.32e-05	0.000181	CcSEcCtD
Sunitinib—Rash—Methotrexate—multiple sclerosis	2.3e-05	0.00018	CcSEcCtD
Sunitinib—Dermatitis—Methotrexate—multiple sclerosis	2.3e-05	0.000179	CcSEcCtD
Sunitinib—Headache—Methotrexate—multiple sclerosis	2.28e-05	0.000178	CcSEcCtD
Sunitinib—Nausea—Methotrexate—multiple sclerosis	2.17e-05	0.000169	CcSEcCtD
Sunitinib—ABCB1—nervous system—multiple sclerosis	2.03e-05	0.000183	CbGeAlD
Sunitinib—ABCB1—central nervous system—multiple sclerosis	1.96e-05	0.000176	CbGeAlD
Sunitinib—ABCB1—cerebellum—multiple sclerosis	1.91e-05	0.000172	CbGeAlD
Sunitinib—ABCB1—brain—multiple sclerosis	1.55e-05	0.00014	CbGeAlD
Sunitinib—FGFR2—Immune System—MAPK1—multiple sclerosis	9.67e-07	5.68e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—RRM1—multiple sclerosis	9.66e-07	5.68e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TYK2—multiple sclerosis	9.64e-07	5.67e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TYK2—multiple sclerosis	9.64e-07	5.67e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—STAT3—multiple sclerosis	9.64e-07	5.67e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—MAPK1—multiple sclerosis	9.64e-07	5.67e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—STAT3—multiple sclerosis	9.63e-07	5.66e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—MAPK1—multiple sclerosis	9.55e-07	5.62e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—MAPK1—multiple sclerosis	9.49e-07	5.58e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—MAPK1—multiple sclerosis	9.49e-07	5.58e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—POMC—multiple sclerosis	9.49e-07	5.58e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CD80—multiple sclerosis	9.39e-07	5.52e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CD80—multiple sclerosis	9.34e-07	5.49e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CCL2—multiple sclerosis	9.28e-07	5.46e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—STAT3—multiple sclerosis	9.28e-07	5.45e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—POMC—multiple sclerosis	9.26e-07	5.44e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—MYC—multiple sclerosis	9.24e-07	5.43e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—STAT3—multiple sclerosis	9.22e-07	5.42e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—TGFB1—multiple sclerosis	9.22e-07	5.42e-06	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—IL6—multiple sclerosis	9.21e-07	5.42e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TYK2—multiple sclerosis	9.15e-07	5.38e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—STAT3—multiple sclerosis	9.15e-07	5.38e-06	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—IL6—multiple sclerosis	9.14e-07	5.37e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TYK2—multiple sclerosis	9.13e-07	5.37e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—STAT3—multiple sclerosis	9.13e-07	5.37e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—STAT3—multiple sclerosis	9.13e-07	5.37e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—MYC—multiple sclerosis	9.12e-07	5.36e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—TGFB1—multiple sclerosis	9.1e-07	5.35e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—MAPK1—multiple sclerosis	9.08e-07	5.34e-06	CbGpPWpGaD
Sunitinib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.06e-07	5.32e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CCL2—multiple sclerosis	9.06e-07	5.32e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—MAPK1—multiple sclerosis	9.04e-07	5.31e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—MAPK1—multiple sclerosis	9.01e-07	5.3e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—BCHE—multiple sclerosis	9e-07	5.29e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—MAPK1—multiple sclerosis	8.99e-07	5.28e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—IL2—multiple sclerosis	8.99e-07	5.28e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—MYC—multiple sclerosis	8.96e-07	5.27e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—MYC—multiple sclerosis	8.95e-07	5.26e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—TGFB1—multiple sclerosis	8.94e-07	5.25e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—STAT3—multiple sclerosis	8.94e-07	5.25e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—STAT3—multiple sclerosis	8.94e-07	5.25e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CD80—multiple sclerosis	8.93e-07	5.25e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—TGFB1—multiple sclerosis	8.93e-07	5.25e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—MAPK1—multiple sclerosis	8.93e-07	5.25e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—POMC—multiple sclerosis	8.92e-07	5.25e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—STAT3—multiple sclerosis	8.91e-07	5.24e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—POMC—multiple sclerosis	8.88e-07	5.22e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—MAPK1—multiple sclerosis	8.77e-07	5.15e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—MAPK1—multiple sclerosis	8.75e-07	5.15e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CCL2—multiple sclerosis	8.73e-07	5.13e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—STAT3—multiple sclerosis	8.71e-07	5.12e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CCL2—multiple sclerosis	8.68e-07	5.1e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—MYC—multiple sclerosis	8.62e-07	5.07e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—POMC—multiple sclerosis	8.61e-07	5.06e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TGFB1—multiple sclerosis	8.6e-07	5.05e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—STAT3—multiple sclerosis	8.59e-07	5.05e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—MYC—multiple sclerosis	8.56e-07	5.03e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TGFB1—multiple sclerosis	8.54e-07	5.02e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—STAT3—multiple sclerosis	8.54e-07	5.02e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—POMC—multiple sclerosis	8.53e-07	5.01e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—IL2—multiple sclerosis	8.52e-07	5.01e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—MMP9—multiple sclerosis	8.5e-07	5e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—MYC—multiple sclerosis	8.5e-07	5e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—MAPK1—multiple sclerosis	8.5e-07	4.99e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—TGFB1—multiple sclerosis	8.48e-07	4.99e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—MYC—multiple sclerosis	8.48e-07	4.99e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—POMC—multiple sclerosis	8.48e-07	4.99e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—TGFB1—multiple sclerosis	8.46e-07	4.97e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—MAPK1—multiple sclerosis	8.43e-07	4.96e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TYK2—multiple sclerosis	8.43e-07	4.95e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—STAT3—multiple sclerosis	8.43e-07	4.95e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—MAPK1—multiple sclerosis	8.38e-07	4.92e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—MAPK1—multiple sclerosis	8.32e-07	4.89e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—MYC—multiple sclerosis	8.3e-07	4.88e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—MYC—multiple sclerosis	8.3e-07	4.88e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCL2—multiple sclerosis	8.3e-07	4.88e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—MAPK1—multiple sclerosis	8.3e-07	4.88e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—MAPK1—multiple sclerosis	8.3e-07	4.88e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TGFB1—multiple sclerosis	8.28e-07	4.87e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TGFB1—multiple sclerosis	8.28e-07	4.87e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IL2—multiple sclerosis	8.27e-07	4.86e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—IL6—multiple sclerosis	8.23e-07	4.84e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TYK2—multiple sclerosis	8.22e-07	4.83e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—STAT3—multiple sclerosis	8.22e-07	4.83e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IL2—multiple sclerosis	8.17e-07	4.8e-06	CbGpPWpGaD
Sunitinib—YES1—Immune System—IL6—multiple sclerosis	8.17e-07	4.8e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—STAT3—multiple sclerosis	8.16e-07	4.8e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—MAPK1—multiple sclerosis	8.12e-07	4.78e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—MAPK1—multiple sclerosis	8.12e-07	4.78e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—MAPK1—multiple sclerosis	8.12e-07	4.77e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—MAPK1—multiple sclerosis	8.1e-07	4.76e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—MYC—multiple sclerosis	8.09e-07	4.76e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TGFB1—multiple sclerosis	8.07e-07	4.75e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MMP9—multiple sclerosis	8.07e-07	4.74e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IL2—multiple sclerosis	8.03e-07	4.72e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IL2—multiple sclerosis	8.03e-07	4.72e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TYK2—multiple sclerosis	7.93e-07	4.66e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—STAT3—multiple sclerosis	7.93e-07	4.66e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—MAPK1—multiple sclerosis	7.92e-07	4.65e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—IL6—multiple sclerosis	7.9e-07	4.64e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TYK2—multiple sclerosis	7.89e-07	4.64e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—STAT3—multiple sclerosis	7.88e-07	4.63e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—ALB—multiple sclerosis	7.85e-07	4.61e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—MYC—multiple sclerosis	7.83e-07	4.6e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MMP9—multiple sclerosis	7.83e-07	4.6e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—TGFB1—multiple sclerosis	7.81e-07	4.59e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—MAPK1—multiple sclerosis	7.8e-07	4.59e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—ALB—multiple sclerosis	7.78e-07	4.57e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—MAPK1—multiple sclerosis	7.76e-07	4.56e-06	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—IL6—multiple sclerosis	7.75e-07	4.55e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MMP9—multiple sclerosis	7.73e-07	4.55e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—MAPK1—multiple sclerosis	7.66e-07	4.5e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—MYC—multiple sclerosis	7.64e-07	4.49e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—TGFB1—multiple sclerosis	7.62e-07	4.48e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IL2—multiple sclerosis	7.62e-07	4.48e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IL2—multiple sclerosis	7.6e-07	4.47e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MMP9—multiple sclerosis	7.6e-07	4.46e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MMP9—multiple sclerosis	7.6e-07	4.46e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—STAT3—multiple sclerosis	7.56e-07	4.45e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TYK2—multiple sclerosis	7.54e-07	4.43e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—STAT3—multiple sclerosis	7.54e-07	4.43e-06	CbGpPWpGaD
Sunitinib—TYK2—Immune System—IL6—multiple sclerosis	7.52e-07	4.42e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—MAPK1—multiple sclerosis	7.48e-07	4.39e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—IL6—multiple sclerosis	7.43e-07	4.37e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—MAPK1—multiple sclerosis	7.42e-07	4.36e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—IL6—multiple sclerosis	7.41e-07	4.35e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—MYC—multiple sclerosis	7.37e-07	4.33e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—TGFB1—multiple sclerosis	7.35e-07	4.32e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—IL6—multiple sclerosis	7.34e-07	4.32e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—MYC—multiple sclerosis	7.33e-07	4.31e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—TGFB1—multiple sclerosis	7.31e-07	4.3e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—IL6—multiple sclerosis	7.3e-07	4.29e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—IL6—multiple sclerosis	7.3e-07	4.29e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MMP9—multiple sclerosis	7.21e-07	4.24e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—MAPK1—multiple sclerosis	7.21e-07	4.24e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MMP9—multiple sclerosis	7.19e-07	4.23e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—APOE—multiple sclerosis	7.18e-07	4.22e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—STAT3—multiple sclerosis	7.17e-07	4.22e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—MAPK1—multiple sclerosis	7.17e-07	4.21e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—MYC—multiple sclerosis	7.03e-07	4.13e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IL2—multiple sclerosis	7.01e-07	4.12e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TGFB1—multiple sclerosis	7.01e-07	4.12e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—MYC—multiple sclerosis	7e-07	4.12e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—TGFB1—multiple sclerosis	6.98e-07	4.11e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—IL6—multiple sclerosis	6.98e-07	4.1e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—STAT3—multiple sclerosis	6.96e-07	4.09e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—IL6—multiple sclerosis	6.94e-07	4.08e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—IL6—multiple sclerosis	6.92e-07	4.07e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—IL6—multiple sclerosis	6.91e-07	4.06e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—STAT3—multiple sclerosis	6.88e-07	4.04e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—MAPK1—multiple sclerosis	6.87e-07	4.04e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—IL6—multiple sclerosis	6.86e-07	4.03e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—MAPK1—multiple sclerosis	6.85e-07	4.03e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IL2—multiple sclerosis	6.84e-07	4.02e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—STAT3—multiple sclerosis	6.75e-07	3.97e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—STAT3—multiple sclerosis	6.75e-07	3.97e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—IL6—multiple sclerosis	6.74e-07	3.96e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—IL6—multiple sclerosis	6.73e-07	3.95e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MYC—multiple sclerosis	6.66e-07	3.92e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TGFB1—multiple sclerosis	6.65e-07	3.91e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MMP9—multiple sclerosis	6.64e-07	3.9e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IL2—multiple sclerosis	6.6e-07	3.88e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL2—multiple sclerosis	6.56e-07	3.86e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—IL6—multiple sclerosis	6.53e-07	3.84e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MAPK1—multiple sclerosis	6.52e-07	3.83e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—IL6—multiple sclerosis	6.48e-07	3.81e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MMP9—multiple sclerosis	6.48e-07	3.81e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MYC—multiple sclerosis	6.47e-07	3.8e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TGFB1—multiple sclerosis	6.45e-07	3.79e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—IL6—multiple sclerosis	6.44e-07	3.78e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—STAT3—multiple sclerosis	6.41e-07	3.77e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—IL6—multiple sclerosis	6.39e-07	3.76e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—STAT3—multiple sclerosis	6.39e-07	3.76e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MYC—multiple sclerosis	6.39e-07	3.76e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—IL6—multiple sclerosis	6.38e-07	3.75e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—IL6—multiple sclerosis	6.38e-07	3.75e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TGFB1—multiple sclerosis	6.37e-07	3.75e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MAPK1—multiple sclerosis	6.33e-07	3.72e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MYC—multiple sclerosis	6.28e-07	3.69e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MYC—multiple sclerosis	6.28e-07	3.69e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL2—multiple sclerosis	6.27e-07	3.69e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TGFB1—multiple sclerosis	6.26e-07	3.68e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TGFB1—multiple sclerosis	6.26e-07	3.68e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MAPK1—multiple sclerosis	6.25e-07	3.67e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MMP9—multiple sclerosis	6.24e-07	3.67e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—IL6—multiple sclerosis	6.24e-07	3.67e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—IL6—multiple sclerosis	6.24e-07	3.67e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—IL6—multiple sclerosis	6.24e-07	3.67e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—IL6—multiple sclerosis	6.22e-07	3.66e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MMP9—multiple sclerosis	6.21e-07	3.65e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—POMC—multiple sclerosis	6.17e-07	3.62e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MAPK1—multiple sclerosis	6.14e-07	3.61e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MAPK1—multiple sclerosis	6.14e-07	3.61e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—IL6—multiple sclerosis	6.08e-07	3.58e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—IL6—multiple sclerosis	6e-07	3.53e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—IL6—multiple sclerosis	5.97e-07	3.51e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MYC—multiple sclerosis	5.96e-07	3.5e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TGFB1—multiple sclerosis	5.94e-07	3.49e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MYC—multiple sclerosis	5.94e-07	3.49e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MMP9—multiple sclerosis	5.93e-07	3.49e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TGFB1—multiple sclerosis	5.93e-07	3.48e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—STAT3—multiple sclerosis	5.9e-07	3.47e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—IL6—multiple sclerosis	5.89e-07	3.46e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MAPK1—multiple sclerosis	5.83e-07	3.42e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MAPK1—multiple sclerosis	5.81e-07	3.42e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—STAT3—multiple sclerosis	5.76e-07	3.39e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—IL6—multiple sclerosis	5.74e-07	3.38e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—IL6—multiple sclerosis	5.7e-07	3.35e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—ALB—multiple sclerosis	5.62e-07	3.3e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—STAT3—multiple sclerosis	5.55e-07	3.26e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—BCHE—multiple sclerosis	5.55e-07	3.26e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—IL6—multiple sclerosis	5.54e-07	3.25e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—STAT3—multiple sclerosis	5.52e-07	3.25e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—IL6—multiple sclerosis	5.51e-07	3.24e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MYC—multiple sclerosis	5.48e-07	3.22e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TGFB1—multiple sclerosis	5.47e-07	3.22e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—APOE—multiple sclerosis	5.42e-07	3.18e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MAPK1—multiple sclerosis	5.36e-07	3.15e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MYC—multiple sclerosis	5.35e-07	3.15e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TGFB1—multiple sclerosis	5.34e-07	3.14e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—IL6—multiple sclerosis	5.28e-07	3.1e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—STAT3—multiple sclerosis	5.28e-07	3.1e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—IL6—multiple sclerosis	5.26e-07	3.09e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MAPK1—multiple sclerosis	5.24e-07	3.08e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MYC—multiple sclerosis	5.16e-07	3.03e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TGFB1—multiple sclerosis	5.15e-07	3.02e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MYC—multiple sclerosis	5.13e-07	3.02e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TGFB1—multiple sclerosis	5.12e-07	3.01e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MAPK1—multiple sclerosis	5.05e-07	2.97e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MAPK1—multiple sclerosis	5.02e-07	2.95e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—IL6—multiple sclerosis	5.01e-07	2.94e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MYC—multiple sclerosis	4.9e-07	2.88e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TGFB1—multiple sclerosis	4.89e-07	2.88e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IL6—multiple sclerosis	4.86e-07	2.86e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IL6—multiple sclerosis	4.8e-07	2.82e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MAPK1—multiple sclerosis	4.8e-07	2.82e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IL6—multiple sclerosis	4.72e-07	2.77e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IL6—multiple sclerosis	4.72e-07	2.77e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—POMC—multiple sclerosis	4.65e-07	2.74e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IL6—multiple sclerosis	4.48e-07	2.63e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IL6—multiple sclerosis	4.47e-07	2.62e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ALB—multiple sclerosis	4.24e-07	2.49e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IL6—multiple sclerosis	4.12e-07	2.42e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IL6—multiple sclerosis	4.02e-07	2.36e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IL6—multiple sclerosis	3.88e-07	2.28e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL6—multiple sclerosis	3.86e-07	2.27e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL6—multiple sclerosis	3.69e-07	2.17e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—APOE—multiple sclerosis	3.34e-07	1.96e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—POMC—multiple sclerosis	2.87e-07	1.69e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ALB—multiple sclerosis	2.61e-07	1.54e-06	CbGpPWpGaD
